Equities analysts expect Aimmune Therapeutics, Inc. (NASDAQ:AIMT) to announce earnings of ($0.72) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Aimmune Therapeutics’ earnings. The highest EPS estimate is ($0.69) and the lowest is ($0.76). Aimmune Therapeutics posted earnings of ($0.53) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 35.8%. The business is scheduled to announce its next quarterly earnings report on Monday, November 13th.
On average, analysts expect that Aimmune Therapeutics will report full-year earnings of ($2.63) per share for the current fiscal year, with EPS estimates ranging from ($2.72) to ($2.54). For the next fiscal year, analysts forecast that the business will report earnings of ($3.22) per share, with EPS estimates ranging from ($3.50) to ($3.05). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that cover Aimmune Therapeutics.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01).
A number of brokerages have commented on AIMT. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Wedbush reiterated an “ourperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research report on Monday, August 14th. BidaskClub lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Piper Jaffray Companies set a $38.00 price objective on Aimmune Therapeutics and gave the company a “buy” rating in a research report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $40.00.
In other news, insider Susan E. Barrowcliffe sold 20,000 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $25.00, for a total value of $500,000.00. Following the transaction, the insider now owns 20,000 shares of the company’s stock, valued at approximately $500,000. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Stephen George Dilly sold 100,000 shares of the stock in a transaction on Monday, September 25th. The shares were sold at an average price of $25.01, for a total value of $2,501,000.00. The disclosure for this sale can be found here. Insiders sold a total of 331,306 shares of company stock worth $8,053,785 over the last quarter. Corporate insiders own 24.56% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Aimmune Therapeutics by 12.6% in the 2nd quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock valued at $50,923,000 after purchasing an additional 276,978 shares during the period. Wellington Management Group LLP lifted its stake in shares of Aimmune Therapeutics by 641.2% in the 1st quarter. Wellington Management Group LLP now owns 2,316,553 shares of the biotechnology company’s stock valued at $50,339,000 after purchasing an additional 2,004,023 shares during the period. Eagle Asset Management Inc. lifted its stake in shares of Aimmune Therapeutics by 6.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 2,270,160 shares of the biotechnology company’s stock valued at $46,674,000 after purchasing an additional 135,374 shares during the period. Palo Alto Investors LLC lifted its stake in shares of Aimmune Therapeutics by 9.9% in the 2nd quarter. Palo Alto Investors LLC now owns 1,289,719 shares of the biotechnology company’s stock valued at $26,517,000 after purchasing an additional 116,221 shares during the period. Finally, State Street Corp lifted its stake in shares of Aimmune Therapeutics by 26.6% in the 2nd quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock valued at $22,351,000 after purchasing an additional 228,429 shares during the period. 72.90% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Aimmune Therapeutics, Inc. (AIMT) Expected to Post Earnings of -$0.72 Per Share” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/10/17/aimmune-therapeutics-inc-aimt-expected-to-post-earnings-of-0-72-per-share.html.
Aimmune Therapeutics (NASDAQ:AIMT) traded down 1.31% during mid-day trading on Tuesday, hitting $25.56. The stock had a trading volume of 311,643 shares. The firm’s market cap is $1.29 billion. The stock has a 50 day moving average of $24.54 and a 200-day moving average of $24.54. Aimmune Therapeutics has a 1-year low of $14.87 and a 1-year high of $27.31.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.